Challenges and material innovations in drug delivery to central nervous system tumors
Source abstract
Abstract
Central nervous system (CNS) tumors, encompassing a diverse array of neoplasms in the brain and spinal cord, pose significant therapeutic challenges due to their intricate anatomy and the protective presence of the blood-brain barrier (BBB). The primary treatment obstacle is the effective delivery of therapeutics to the tumor site, which is hindered by multiple physiological, biological, and technical barriers, including the BBB. This comprehensive review highlights recent advancements in material science and nanotechnology aimed at surmounting these delivery challenges, with a focus on the development and application of nanomaterials. Nanomaterials emerge as potent tools in designing innovative drug delivery systems that demonstrate the potential to overcome the limitations posed by CNS tumors. The review delves into various strategies, including the use of lipid nanoparticles, polymeric nanoparticles, and inorganic nanoparticles, all of which are engineered to enhance drug stability, BBB penetration, and targeted tumor delivery. Additionally, this review highlights the burgeoning role of theranostic nanoparticles, integrating therapeutic and diagnostic functionalities to optimize treatment efficacy. The exploration extends to biocompatible materials like biodegradable polymers, liposomes, and advanced material-integrated delivery systems such as implantable drug-eluting devices and microfabricated devices. Despite promising preclinical results, the translation of these material-based strategies into clinical practice necessitates further research and optimization.
Source: europepmc · Quality: candidate unverified · Source record ↗
Research context
OpenAlex topics: Glioma Diagnosis and Treatment · Nanoplatforms for cancer theranostics · Nanoparticle-Based Drug Delivery
SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.
References (100+)
Show source-provided references
1. Burden and trends of brain and central nervous system cancer from 1990 to 2019 at the global, regional, and country levels10.1186/s13690-022-00965-5 ↗
2. Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries10.3322/caac.21834 ↗
3. [Cancer incidence and mortality in China, 2022]
4. Disease burden, risk factors, and trends of primary central nervous system (CNS) cancer: a global study of registries data10.1093/neuonc/noac213 ↗
5. Brain metastases: a Society for Neuro-Oncology (SNO) consensus review on current management and future directions10.1093/neuonc/noac118 ↗
6. Harnessing immunotherapy for brain metastases: insights into tumor-brain microenvironment interactions and emerging treatment modalities10.1186/s13045-023-01518-1 ↗
7. A multidisciplinary management algorithm for brain metastases
8. The blood-brain barrier: structure, regulation, and drug delivery10.1038/s41392-023-01481-w ↗
9. Drug delivery to the central nervous system10.1038/s41578-021-00394-w ↗
10. Current challenges and opportunities in treating glioblastoma10.1124/pr.117.014944 ↗
11. On the rate and extent of drug delivery to the brain10.1007/s11095-007-9502-2 ↗
12. Convection-enhanced drug delivery for glioblastoma: a review10.1007/s11060-020-03408-9 ↗
13. MEMS devices for drug delivery10.1016/j.addr.2017.11.003 ↗
14. Local strategies and delivery systems for the treatment of malignant gliomas10.1080/1061186X.2018.1509982 ↗
15. Biocompatible and nanoenabled technologies for biological modulation10.1002/admt.202100216 ↗
16. MMP-2-triggered, mitochondria-targeted PROTAC-PDT therapy of breast cancer and brain metastases inhibition10.1038/s41467-024-54854-2 ↗
17. Direct cytosolic delivery of siRNA via cell membrane fusion using cholesterol-enriched exosomes10.1038/s41565-024-01785-0 ↗
18. Polymer-locking fusogenic liposomes for glioblastoma-targeted siRNA delivery and CRISPR-Cas gene editing10.1038/s41565-024-01769-0 ↗
19. Simultaneous targeting of peripheral and brain tumors with a therapeutic nanoparticle to disrupt metabolic adaptability at both sites10.1073/pnas.2318119121 ↗
20. Blood-brain barrier penetrating nanovehicles for interfering with mitochondrial electron flow in glioblastoma10.1021/acsnano.3c12434 ↗
21. Self-disassembling and oxygen-generating porphyrin-lipoprotein nanoparticle for targeted glioblastoma resection and enhanced photodynamic therapy
22. Recent advances in biomimetic strategies for the immunotherapy of glioblastoma10.1016/j.biomaterials.2024.122694 ↗
23. P-selectin-targeted nanocarriers induce active crossing of the blood-brain barrier via caveolin-1-dependent transcytosis10.1038/s41563-023-01481-9 ↗
24. Biomimetic nanosonosensitizers combined with noninvasive ultrasound actuation to reverse drug resistance and sonodynamic-enhanced chemotherapy against orthotopic glioblastoma10.1021/acsnano.2c08861 ↗
25. Dual-site förster resonance energy transfer route of upconversion nanoparticles-based brain-targeted nanotheranostic boosts the near-infrared phototherapy of glioma10.1021/acsnano.3c03724 ↗
26. Self-assembled aza-boron-dipyrromethene-based H2S prodrug for synergistic ferroptosis-enabled gas and sonodynamic tumor therapies
27. Nanomaterial-mediated CNS delivery of diagnostic and therapeutic agents10.1016/j.addr.2011.11.014 ↗
28. Applications of nanotechnology in drug delivery to the central nervous system10.1016/j.biopha.2018.12.133 ↗
29. Diagnostic, therapeutic, and prognostic implications of the 2021 World Health Organization classification of tumors of the central nervous system10.1002/cncr.33918 ↗
30. Breaching the blood–brain tumor barrier for tumor therapy10.3390/cancers13102391 ↗
31. The blood–brain barrier: structure, regulation, and drug delivery
32. Central nervous system cancers, version 3.2020, NCCN clinical practice guidelines in oncology10.6004/jnccn.2020.0052 ↗
33. The blood-brain barrier and blood-tumour barrier in brain tumours and metastases10.1038/s41568-019-0205-x ↗
34. State of the art of chemotherapy for the treatment of central nervous system metastases from non-small cell lung cancer10.21037/tlcr.2016.11.01 ↗
35. A review on surgical treatment options in gliomas
36. l
37. Effect of intra- and inter-tumoral heterogeneity on molecular characteristics of primary IDH-wild type glioblastoma revealed by single-cell analysis10.1111/cns.13396 ↗
38. Glioblastoma cells: a heterogeneous and fatal tumor interacting with the parenchyma10.1016/j.lfs.2011.04.022 ↗
39. Dealing with danger in the CNS: the response of the immune system to injury10.1016/j.neuron.2015.05.019 ↗
40. Immune microenvironment landscape in CNS tumors and role in responses to immunotherapy10.3390/cells10082032 ↗
41. Harnessing innate immune pathways for therapeutic advancement in cancer10.1038/s41392-024-01765-9 ↗
42. Oxidative stress in the tumor microenvironment and its relevance to cancer immunotherapy10.3390/cancers13050986 ↗
43. Immune dynamics in the CNS and its barriers during homeostasis and disease10.1111/imr.13066 ↗
44. Immunological defense of CNS barriers against infections10.1016/j.immuni.2022.04.012 ↗
45. Adult central nervous system tumors treatment (PDQ®)
46. Drug resistance in brain diseases and the role of drug efflux transporters10.1038/nrn1728 ↗
47. Long-term cognitive dysfunction after radiation therapy for primary brain tumors10.1080/0284186X.2018.1557786 ↗
48. Radioresistance in glioblastoma and the development of radiosensitizers10.3390/cancers12092511 ↗
49. Current status and recent advances in reirradiation of glioblastoma
50. Editing a gateway for cell therapy across the blood-brain barrier10.1093/brain/awac393 ↗
51. Advanced drug delivery 2020 and beyond: perspectives on the future10.1016/j.addr.2020.06.018 ↗
52. The blood-brain barrier: structure, regulation, and drug delivery10.1038/s41392-023-01481-w ↗
53. Strategies for delivering therapeutics across the blood-brain barrier10.1038/s41573-021-00139-y ↗
54. Strategies for structural modification of small molecules to improve blood-brain barrier penetration: a recent perspective10.1021/acs.jmedchem.1c00910 ↗
55. Advances in local therapy for glioblastoma - taking the fight to the tumour10.1038/s41582-022-00621-0 ↗
56. Rationally designed drug delivery systems for the local treatment of resected glioblastoma10.1016/j.addr.2021.113951 ↗
57. Biodegradable wafers releasing Temozolomide and Carmustine for the treatment of brain cancer10.1016/j.jconrel.2018.12.048 ↗
58. A phase 3 trial of local chemotherapy with biodegradable carmustine (BCNU) wafers (Gliadel wafers) in patients with primary malignant glioma10.1093/neuonc/5.2.79 ↗
59. Long-term results of carmustine wafer implantation for newly diagnosed glioblastomas: a controlled propensity-matched analysis of a French multicenter cohort10.1093/neuonc/nov126 ↗
60. Designing next-generation local drug delivery vehicles for glioblastoma adjuvant chemotherapy: lessons from the clinic10.1002/adhm.201801391 ↗
61. Cerebral edema associated with Gliadel wafers: two case studies10.1215/S1152851704000614 ↗
62. Eosinophilic meningitis triggered by implanted Gliadel wafers: case report10.3171/2016.4.JNS152771 ↗
63. Editorial. Chronic convection-enhanced delivery: the next frontier in regional drug infusion for glioblastoma10.3171/2019.4.JNS19614 ↗
64. Convection-enhanced delivery for the treatment of glioblastoma10.1093/neuonc/nou354 ↗
65. Chronic convection-enhanced intratumoural delivery of chemotherapy for glioblastoma10.1016/S1470-2045(22)00626-X ↗
66. Chronic convection-enhanced delivery of topotecan for patients with recurrent glioblastoma: a first-in-patient, single-centre, single-arm, phase 1b trial10.1016/S1470-2045(22)00599-X ↗
67. Intranasal delivery of mesenchymal stem cell secretome repairs the brain of Alzheimer's mice10.1038/s41418-020-0592-2 ↗
68. Intranasal nanotherapeutics for brain targeting and clinical studies in Parkinson's disease10.1016/j.jconrel.2023.04.021 ↗
69. Nose-to-brain delivery of lipid-based nanosystems for epileptic seizures and anxiety crisis10.1016/j.jconrel.2018.12.049 ↗
70. Brain targeted delivery of carmustine using chitosan coated nanoparticles via nasal route for glioblastoma treatment10.1016/j.ijbiomac.2022.08.210 ↗
71. Intranasal pathway for nanoparticles to enter the central nervous system10.1021/acs.nanolett.2c05056 ↗
72. Convolutions in the rendition of nose to brain therapeutics from bench to bedside: feats & fallacies10.1016/j.jconrel.2021.12.009 ↗
73. Intranasal delivery of functionalized polymeric nanomaterials to the brain
74. Intrathecal delivery of Macromolecules: clinical status and emerging technologies10.1016/j.addr.2023.114949 ↗
75. Intrathecal delivery and its applications in leptomeningeal disease10.1016/j.addr.2022.114338 ↗
76. Perivascular spaces in the brain: anatomy, physiology and pathology10.1038/s41582-020-0312-z ↗
77. Harnessing cerebrospinal fluid circulation for drug delivery to brain tissues10.1016/j.addr.2021.03.002 ↗
78. Intracerebroventricular administration for delivery of antiseizure therapeutics: challenges and opportunities10.1111/epi.17625 ↗
79. Dexmedetomidine enhances glymphatic brain delivery of intrathecally administered drugs10.1016/j.jconrel.2019.05.005 ↗
80. Noninvasive ultrasonic induction of cerebrospinal fluid flow enhances intrathecal drug delivery10.1016/j.jconrel.2022.06.067 ↗
81. Ommaya reservoir system for the treatment of cystic craniopharyngiomas: surgical results in a series of 11 adult patients and review of the literature10.1016/j.wneu.2019.07.217 ↗
82. Ommaya reservoir insertion: a technical note
83. Intrathecal drug delivery in the era of nanomedicine
84. Recent progress and new challenges in modeling of human pluripotent stem cell-derived blood-brain barrier10.7150/thno.63195 ↗
85. Blood-brain barrier: from physiology to disease and back10.1152/physrev.00050.2017 ↗
86. Approaches to transport therapeutic drugs across the blood-brain barrier to treat brain diseases10.1016/j.nbd.2009.07.028 ↗
87. The blood-brain barrier and blood-tumour barrier in brain tumours and metastases10.1038/s41568-019-0205-x ↗
88. Is the blood-brain barrier really disrupted in all glioblastomas? A critical assessment of existing clinical data10.1093/neuonc/nox175 ↗
89. Physiologically-based pharmacokinetic (PBPK) modelling of transporter mediated drug absorption, clearance and drug-drug interactions10.2174/1389200221999210101233340 ↗
90. The need for mathematical modelling of spatial drug distribution within the brain10.1186/s12987-019-0133-x ↗
91. Brain drug-metabolizing cytochrome P450 enzymes are active in vivo, demonstrated by mechanism-based enzyme inhibition10.1038/npp.2008.110 ↗
92. Design, synthesis and evaluation of novel monoamine oxidase B (MAO-B) inhibitors with improved pharmacokinetic properties for Parkinson's disease10.1016/j.ejmech.2023.115308 ↗
93. Esterase-responsive and size-optimized prodrug nanoparticles for effective intracranial drug delivery and glioblastoma treatment
94. Regulation of brain drug metabolizing enzymes and transporters by nuclear receptors10.1080/03602532.2018.1554673 ↗
95. The UDP-glucuronosyltransferases of the blood-brain barrier: their role in drug metabolism and detoxication10.3389/fncel.2014.00349 ↗
96. Neuronal activity regulates blood-brain barrier efflux transport through endothelial circadian genes10.1016/j.neuron.2020.09.002 ↗
97. The glymphatic system: implications for drugs for central nervous system diseases10.1038/s41573-022-00500-9 ↗
98. Modulation of P-glycoprotein at the blood-brain barrier: opportunities to improve central nervous system pharmacotherapy10.1124/pr.107.07109 ↗
99. Tailoring of P-glycoprotein for effective transportation of actives across blood-brain-barrier10.1016/j.jconrel.2021.05.046 ↗
100. Recent advances in the in vitro and in vivo methods to assess impact of P-glycoprotein and breast cancer resistance protein transporters in central nervous system drug disposition10.1002/bdd.2345 ↗